



Express Mail Label No.: EL 405942 US
Date of Deposit: October 4, 2002

10-07-02
GP 1647
Ref sep.
Attorney Docket No. 14445-501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chalifour *et al.*
SERIAL NUMBER: 09/724,842 EXAMINER: Sharon L. Turner, Ph.D.
FILING DATE: November 28, 2000 ART UNIT: 1647
FOR: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S AND
AMYLOID RELATED DISEASES

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

October 4, 2002
Boston, Massachusetts

Commissioner for Patents
Washington, D.C. 20231
ATTN: Examiner Sharon Turner, Art Unit 1647

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- ☒ Copy of Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.);
- ☒ Response to the Communication Mailed 09/04/02 (4 pgs.);
- ☒ Amended Figures (Figs. 1, 2, 3 and 7; 4 sheets)
- ☒ Paper Copy of Corrected Sequence Listing (24 pgs.);
- ☒ Computer-Readable Copy of Sequence Listing (one diskette);
- ☒ Statement in Support of Computer Readable Form Submission (1 pg.); and
- ☒ Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.



30623


PATENT TRADEMARK OFFICE

Applicants: Chalifour et al.
U.S.S.N.: 09/724,842

The Commissioner is hereby authorized to credit any overpayment or charge any fee deficiency to Deposit Account No. 50-0311, Reference No. 14445-501. A duplicate of this Transmittal Letter is enclosed.

Respectfully submitted,

Dated: October 4, 2002


Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: *The specifications reference to seq ID NO 25-27 differs from that noted in the sequence listing paper and CRF copies*
*see **

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

RECEIVED

OCT 09 2002

TECH CENTER 1600/2900

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY